- Home
- MRCC vs ABOS Comparison
MRCC vs ABOS Comparison
Compare MRCC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | ABOS |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.2M | 113.9M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MRCC | ABOS |
|---|---|---|
| Price | $6.54 | $2.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $8.00 | $7.67 |
| AVG Volume (30 Days) | 141.4K | ★ 167.9K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 11.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $0.86 |
| 52 Week High | $8.85 | $2.46 |
Technical Indicators
Market Signals| Indicator | MRCC | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 50.02 |
| Support Level | $5.99 | $1.90 |
| Resistance Level | $6.80 | $2.39 |
| Average True Range (ATR) | 0.21 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 73.97 | 24.43 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.